

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

09 Jun 2026

### Investigating the effect of low dose vitamin D on intensity of dysmenorrhea

#### Protocol summary

##### Study aim

Determining the intensity of dysmenorrhea pain in the two intervention and control groups before, immediately, 1, 3 and 6 months after the intervention

##### Design

Double Blind Randomized Placebo Controlled Trial

##### Settings and conduct

Participants will be recruited via convenience sampling by referring to different faculties of Qazvin University of Medical Sciences. eligible people with the desire to participate in the study are registered. Then random allocation in two groups will be done by balanced block randomization method with block size of 4. Participants, researchers, outcome assessors, and data analysts will be blinded to the study groups.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: 1. Moderate to severe primary dysmenorrhea (score higher than 4 based on visual pain scale) 2. Single 3. At reproductive ages (18 to 35 years) 4. Student of Qarvin University of Medical Sciences 5. Willingness to participate in the study Exclusion criteria: 1. Existence of secondary dysmenorrhea and its predisposing factors such as history of endometriosis, adenomyosis, subacute endometritis, pelvic inflammatory disease, copper intrauterine devices, ovarian cysts, congenital pelvic malformations and cervical stenosis based on individual statement. 2. History of known mental illness based on individual statement 3. Drug addiction based on a person's statement 4. Probability of graduation during the follow-up period 5. Use vitamin D or calcium supplements 6. Concomitant use of corticosteroids, anticonvulsants, anti-tuberculosis, anti-hypertensive drugs that interfere with the absorption of vitamin D

##### Intervention groups

Intervention group with vitamin capsule 1000 units / control group with placebo capsule

##### Main outcome variables

Intensity of dysmenorrhea pain

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20180218038789N3**

Registration date: **2020-09-15, 1399/06/25**

Registration timing: **prospective**

Last update: **2020-09-15, 1399/06/25**

Update count: **0**

##### Registration date

2020-09-15, 1399/06/25

##### Registrant information

##### Name

Zainab Alimoradi

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 28 3333 6003

##### Email address

z.alimoradi@qums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2020-10-22, 1399/08/01

##### Expected recruitment end date

2021-05-20, 1400/02/30

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Investigating the effect of low dose vitamin D on intensity of dysmenorrhea

**Public title**

Effect of vitamin D on intensity of dysmenorrhea

**Purpose**

Prevention

**Inclusion/Exclusion criteria****Inclusion criteria:**

Moderate to severe primary dysmenorrhea (score above 4 based on visual pain scale) Being Single Being at reproductive ages (18 to 35 years) Student of Qazvin University of Medical Sciences Willingness to participate in the study

**Exclusion criteria:**

Presence of secondary dysmenorrhea and its underlying factors such as history of endometriosis, adenomyosis, subacute endometritis, pelvic inflammatory disease, copper intrauterine devices, ovarian cysts, congenital pelvic malformations and cervical stenosis based on individual statement Concurrent use of corticosteroids, anticonvulsants, anti-TB, anti-hypertension, which interfere with the absorption of vitamin D. Use vitamin D or calcium supplements Probability of graduation during the follow-up period History of known mental illness based on individual statement Drug addiction based on self disclosure

**Age**

From **18 years** old to **35 years** old

**Gender**

Female

**Phase**

3

**Groups that have been masked**

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

**Sample size**

Target sample size: **92**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Individuals will be assigned to intervention groups and placebo by block randomization method using 4 blocks. Given that the two groups will be studied, blocks with size of 4 are used and each letter is assigned to a group (A: intervention group, B: comparison group). All possible modes are written and numbered for a block of 4, such as: 1.AABB 2.ABAB 3.BBAA 4.BABA 5.ABBA 6.BAAB 7.--- Then, in a simple random method (using a table of random numbers), a number of numbers are selected from the block numbers and by writing the contents of the blocks related to those numbers (until the specified sample size is obtained), The random assignment sequence is specified. For example, if the numbers obtained are 3, 2, 2, 1, etc., respectively, the assignment sequence will be as follows: AABB ABAB ABAB BBAAThe type of intervention is then written based on the allocation sequence and placed in envelopes in a matte

package. The envelopes are coded in order. In this case, for the person who receives the intervention code 1, a questionnaire with the same code is completed.

**Blinding (investigator's opinion)**

Triple blinded

**Blinding description**

Blinding of medicine and placebo capsules will be done by the pharmaceutical company. The drug and placebo will be similar in shape, color and smell and will be provided to the researcher with the code a, b. The participant, researcher, outcome assessor, and data analyst will be unaware of the codes until the end of the analysis. At the end of the analysis, codes specific to each group will be taken from the pharmaceutical company.

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Qazvin University of Medical Sciences

**Street address**

Bahonar Boulevard, Qazvin University of Medical Sciences

**City**

Qazvin

**Province**

Qazvin

**Postal code**

3419759811

**Approval date**

2020-05-17, 1399/02/28

**Ethics committee reference number**

IR.QUMS.REC.1399.033

**Health conditions studied****1****Description of health condition studied**

Primary dysmenorrhea

**ICD-10 code**

N94.4

**ICD-10 code description**

Primary dysmenorrhea

**Primary outcomes**

## 1

### **Description**

Intensity of dysmenorrhea pain

### **Timepoint**

Before, Immediately, 1, 3, 6 months after intervention

### **Method of measurement**

Visual analogue scale

## **Secondary outcomes**

## 1

### **Description**

Duration of dysmenorrhea pain

### **Timepoint**

Before, immediately, 1, 3 and 6 months after the intervention

### **Method of measurement**

Individual report of pain duration by day

## 2

### **Description**

Need to use pain killer

### **Timepoint**

Before, immediately, 1, 3 and 6 months after the intervention

### **Method of measurement**

Individual report of need to use pain killer

## 3

### **Description**

Menstrual distress

### **Timepoint**

Before, immediately, 1, 3 and 6 months after the intervention

### **Method of measurement**

Moos questionnaire of menstrual distress

## **Intervention groups**

## 1

### **Description**

Intervention group: Capsule of Vitamin D 1000 IU// These capsules will be provided by Nanohiat Pharmaceutical Company. Vitamin D capsules with a dose of 1000 units are prepared for daily use. The intervention plan is to prescribe one capsule daily for two consecutive months. Each eligible participant is asked to start taking the capsules when menstrual bleeding begins and to take one capsule daily for two months after the initial assessments.

### **Category**

Prevention

## 2

### **Description**

Control group: Placebo capsule// These capsules will be provided by the same company in exactly the same way

as the capsules containing the drug in terms of size, shape and color. The intervention plan is to prescribe one capsule daily for two consecutive months. Each eligible participant, after initial assessments, is asked to start taking the capsules when menstrual bleeding begins and to take one capsule daily for two months.

### **Category**

Placebo

## **Recruitment centers**

## 1

### **Recruitment center**

#### **Name of recruitment center**

Faculties of Qazvin University ofg a

#### **Full name of responsible person**

Zainab Alimoradi

#### **Street address**

Bahonar Boulevard, Qazvin University of Medical Sciences

#### **City**

Qazvin

#### **Province**

Qazvin

#### **Postal code**

3419759811

#### **Phone**

+98 28 3333 6002

#### **Email**

zainabalimoradi.sbm.ac.ir@gmail.com

## **Sponsors / Funding sources**

## 1

### **Sponsor**

#### **Name of organization / entity**

Qazvin University of Medical Sciences

#### **Full name of responsible person**

Dr. Mohammad Mahdi Emam Jomeh

#### **Street address**

Bahonar Boulevard, Qazvin University of Medical Sciences

#### **City**

Qazvin

#### **Province**

Qazvin

#### **Postal code**

3419759811

#### **Phone**

+98 28 3333 6002

#### **Email**

memamjomeh@qums.ac.ir

### **Grant name**

### **Grant code / Reference number**

### **Is the source of funding the same sponsor organization/entity?**

Yes

### **Title of funding source**

Qazvin University of Medical Sciences

### **Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin**

**Type of organization providing the funding**

Academic

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Qazvin University of Medical Sciences

**Full name of responsible person**

Zainab Alimoradi

**Position**

Assistant Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Reproductive Health

**Street address**

Bahonar Boulevard, Qazvin University of Medical Sciences

**City**

Qazvin

**Province**

Qazvin

**Postal code**

3419759811

**Phone**

+98 28 3333 6002

**Email**

zainabalimoradi.sbm.ac.ir@gmail.com

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Qazvin University of Medical Sciences

**Full name of responsible person**

Zainab Alimoradi

**Position**

Assistant professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Reproductive Health

**Street address**

Bahonar Boulevard, Qazvin University of Medical Sciences

**City**

Qazvin

**Province**

Qazvin

**Postal code**

3419759811

**Phone**

0098283336002

**Email**

zainabalimoradi.sbm.ac.ir@gmail.com

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

Qazvin University of Medical Sciences

**Full name of responsible person**

Zainab Alimoradi

**Position**

Assistant professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Reproductive Health

**Street address**

Bahonar Boulevard, Qazvin University of Medical Sciences

**City**

Qazvin

**Province**

Qazvin

**Postal code**

3419759811

**Phone**

+98 28 3333 6002

**Email**

zainabalimoradi.sbm.ac.ir@gmail.com

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Not applicable

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Yes - There is a plan to make this available

**Data Dictionary**

Yes - There is a plan to make this available

**Title and more details about the data/document**

Participants' personal data is shared in an unidentifiable manner along with the publication of the final article

**When the data will become available and for how long**

After the completion of study

**To whom data/document is available**

there is no limitation

**Under which criteria data/document could be used**

there is no limitation

**From where data/document is obtainable**

Email to corresponding author

**What processes are involved for a request to access data/document**

Specify the purpose of the need to access the data

## Comments